ReviewActa pharmaceutica Sinica. B2024

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.

Shuang Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.